Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer


A Phase II Trial of Combined Modality Therapy With Growth Factor Support for Patients With Limited Stage Small Cell Lung Cancer


Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Colony-stimulating factors, such as G-CSF or pegfilgrastim, may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover from the side effects of chemotherapy and radiation therapy.


This phase II trial is studying G-CSF and pegfilgrastim to see how well they work in treating neutropenia in patients undergoing combination chemotherapy and radiation therapy for limited stage small cell lung cancer.

Study Status: Completed


Condition Intervention Phase
Lung Cancer Biological: filgrastim
Biological: pegfilgrastim
Drug: cisplatin
Drug: etoposide
Radiation: radiation therapy
Phase 2

Verified by Radiation Therapy Oncology Group December, 2013

Sponsored by: Radiation Therapy Oncology Group
Information provided by: Radiation Therapy Oncology Group identifier: NCT00554463

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Rogerio C. Lilenbaum, MD., Principal Investigator
Ritsuko U. Komaki, MD, FACR., Study Chair
Michael A. Samuels, MD., Study Chair
Jeffrey Crawford, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site